Laurus Labs is currently trading at Rs. 545.40, up by 11.65 points or 2.18% from its previous closing of Rs. 533.75 on the BSE.
The scrip opened at Rs. 550.00 and has touched a high and low of Rs. 556.95 and Rs. 541.30 respectively. So far 33257 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 634.00 on 12-Jun-2017 and a 52 week low of Rs. 468.00 on 03-Feb-2017.
Last one week high and low of the scrip stood at Rs. 556.95 and Rs. 531.15 respectively. The current market cap of the company is Rs. 5778.62 crore.
The promoters holding in the company stood at 30.57%, while Institutions and Non-Institutions held 50.60% and 18.83% respectively.
Laurus Labs has been certified as the ‘Great Place to Work For’, in the large sized organizations category in India, in the 2018 edition of Great Place to Work- a study by Great Place To Work Institute.
Every year, more than 8000 organizations from over 50 countries partner Great Place to Work Institute for assessment, benchmarking and planning actions to assess and strengthen their workplace culture. It is an important step for the organization in its journey to build a High-Trust, High-Performance Culture and Laurus Labs organization has successfully accomplished this milestone.
The Institute assesses workplace culture through 2 primary lenses to evaluate and identify the best cultures. The first lens measures the quality of employee experience through the globally validated survey instrument known as Trust Index.
Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1748.60 |
Dr. Reddys Lab | 1164.70 |
Cipla | 1508.70 |
Lupin | 2035.30 |
Zydus Lifesciences | 903.10 |
View more.. |